Search

Your search keyword '"Badurski, J"' showing total 98 results
Start Over Author "Badurski, J"
98 results on '"Badurski, J"'

4. Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss

Author

Parsons, Camille M., Judge, Andrew, Leyland, Kirsten, Bruyere, Olivier, Dop, Florence Petit, Chapurlat, Roland, Reginster, Jean-yves, Edwards, Mark H., Dennison, Elaine M., Cooper, Cyrus, Inskip, Hazel, Reginster, J. -y., Christiansen, C., Delmas, P., Genant, H., Zacher, J., Bellamy, N., Speirs, C., Breart, G., Meyer, O., Gensburger, D., Arlot, M., Roux, J. -P., Deroisy, R., Sambrook, P., Leeb, B., Verbruggen, A., Bensen, W. G., Hala, T., Holm−bentzen, M., Valter, I., Chevalier, X., Swoboda, B., Adami, S., Kloppenburg, M., Grazuleviciute, E., Badurski, J., Branco, J., Nasonov, E., Navarro, F., Spector, T., Barnsley, L., Hall, S., Jones, G., Klestov, A., March, L., Nash, P., Romas, E., Will, R., Erlacher, L., Leeb, F. B., Resch, H., Rainer, F., Zamani, O., Appelboom, T., Devogelaer, J. P., Kvasz, A., Raeman, F., Beaulieu, A. D., Brown, J., Cividino, A. A., Morin, F., Olszynski, W. P., Raynauld, J. P., Thorne, J. C., Pavelka, K., Alexandersen, P., Hoeck, H. C., Holm-Bentzen, M., Lundqvist, P., Aim, L., Audouy, P., Beaunier, P., Benhamou, C. L., Berenbaum, F., Chabaud, E., Cohen-Solal, M., Delbecq, D., Euller-Ziegler, L., Fardellone, Patrice, Hilliquin, P., Jacquety, E., Jude, N., Lechevalier, D., Mouchet, J. C., Richette, P., Sainte Lorette, E., Schaeverbeke, T., Sebbah, A., Vignot, E., Brabant, T., Burm-Ester, G. R., Grifka, J., Mueller, P. E. M., Bianchi, G., Grassi, W., Di Matteo, L., Modena, V., Di Munno, O., Orto-Lani, S., Punzi, L., Zangari, M., Roorda, L. D., van Riel, P. L. C. M., Czerwinski, E., Gorecki, A., Tlustochowicz, W., da Silva, J. Canas, Gomes, J. A. Melo, Miranda, L. M., Radulescu, F., Alexeeva, L. I., Orlov-Morozov, A. V., Pikhlak, E. G., Pilyaev, V. G., Shostak, N. A., Shmidt, E. I., Zagorodniy, N. V., Rodriguez, L. Arboleya, Ruiz, P. Benito, Carmona, E. Chamizo, Estevez, E. Collantes, Herrero-Beaumont, G., Mola, E. Martin, Moreno, A., Hernandez, A. Naranjo, Sarabia, F. Navarro, Padrino, J. M., Palacios, C., Serna, A. Rodriguez, Ivorra, J. A. Roman, Torrijos, A., Abdulhakim, E., Arden, N., Birrell, F., Donnachie, H., Fraser, W., Keen, R., Sarmiento, R., Stone, M. D., Grp, Sekoia Study, Department of public health, Université de Liège, Service de Rhumatologie et Pathologie Osseuse [Lyon], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), World Health Organization (WHO), World Health Organization, University of Southampton, University of Bristol [Bristol], Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK (BIHR), Department of Public Health, Epidemiology and Health Economics, Center for Permafrost (CENPERM), Department of Geosciences and Natural Resource Management [Copenhagen] (IGN), Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)-Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Queen's University [Kingston, Canada], Department of Computer Science [Auckland], University of Auckland [Auckland], Institut de Recherche sur la Fusion par confinement Magnétique (IRFM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), University of Antwerp (UA), Arkema (Arkema), Hutchinson SA, Chair of Aerodynamics and Fluid Mechanics, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Leiden University Medical Center (LUMC), Universiteit Leiden, CEDOC - Department of Rheumatology, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), CHLO/Hospital Egas Moniz, Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Radio and Space Plasma Physics Group [Leicester] (RSPP), University of Leicester, School of Environmental Sciences, University of Greenwich, Johns Hopkins University (JHU), University of Queensland [Brisbane], Université Laval [Québec] (ULaval), Intergroupe Francophone de Cancérologie Thoracique [Paris] (IFCT), Intergroupe Francophone de Cancérologie thoracique, Institute of Rheumatology, University Prague, Oskar Klein Centre [Stockholm], Stockholm University, Laboratoire de Réactivité de Surface (LRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques (BIOSCAR (UMR_S_1132 / U1132)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de rhumatologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Département de Rhumatologie, CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Sud Francilien, Laboratoire d'Electronique, d'Informatique et d'Image [EA 7508] (Le2i), Université de Technologie de Belfort-Montbeliard (UTBM)-Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] (FHU ACRONIM), CHU Bordeaux [Bordeaux], Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Department of Bone and Joint Diseases, Faculty of Medicine and Health Sciences, Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Departamento de Construcción y Agronomía, Facultad de Ciencias Agrarias y Ambientales, University of Oxford, The University of Sydney, IUMEA, University of Las Palmas de Gran Canaria (ULPGC), the SEKOIA management team, Bradford Teaching Hospitals NHS Foundation Trust [Bradford, Royaume-Uni], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)-Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Centre National de la Recherche Scientifique (CNRS), University of Oxford [Oxford], APH - Aging & Later Life, and Rehabilitation medicine

Subjects
Male, medicine.medical_specialty, Knee Joint, [SDV]Life Sciences [q-bio], Radiography, Osteoarthritis, Thiophenes, Placebo, Severity of Illness Index, Article, law.invention, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Rheumatology, Randomized controlled trial, Strontium ranelate, law, Internal medicine, Severity of illness, Medicine, Humans, skin and connective tissue diseases, Aged, Bone Density Conservation Agents, business.industry, Reproducibility of Results, Middle Aged, Osteoarthritis, Knee, medicine.disease, Multicenter study, Physical therapy, Disease Progression, Female, sense organs, business, medicine.drug
Abstract

Contains fulltext : 202254.pdf (Publisher’s version ) (Closed access) OBJECTIVE: Osteoarthritis-related changes in joint space measurements over time are small and sensitive to measurement error. The Reliable Change Index (RCI) determines whether the magnitude of change observed in an individual can be attributed to true change. This study aimed to examine the RCI as a novel approach to estimating osteoarthritis progression. METHODS: Data were from 167 men and 392 women with knee osteoarthritis (diagnosed using the American College of Rheumatology criteria) randomized to the placebo arm of the 3-year Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA) and assessed annually. The RCI was used to determine whether the magnitude of change in joint space width (JSW) on radiographs between study years was likely to be true or due to measurement error. RESULTS: Between consecutive years, 57-69% of participants had an apparent decrease (change

Published
2019
Full Text
View/download PDF

11. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial

Author

Cauley, J. a., Dennis, Black, Steven, Boonen, Cummings, Steven R., Peter, Mesenbrink, Lisa, Palermo, Zulema, Man, Peyman, Hadji, Horizon Pivotal Fracture Group Horowitz, Reid Ir Z., Orloff, J., Black, D., Cummings, S., Delmas, P., Eastell, R., Reid, Ian R., Boonen, S., Cauley, J., Cosman, F., Lakatos, P., Leung, P. c., Man, Z., Lau, E., Jasqui, S., Mautalen, C., Rosario Jansen, T., Caminis, J., Eriksen, E. f., Mesenbrink, P., Raisz, L., Bauer, P., Compston, J., Demets, D., Hirschberg, R., Johnell, O., Ralston, S., Wallace, R., Farkough, M., Flood, M., Bauer, D., Palermo, L., Lang, T., Kerzberg, E., Ridruejo, M., Tate, G., Velasco, J., Hooper, M., Kotowicz, M., Nash, P., Prince, R., Roberts, A., Sambrook, P., Dobnig, H., Finkenstedt, G., Hoefle, G., Klaushofer, K., Pecherstorfer, M., Peichl, P., Body, J., Devogelaer, J. p., Geusens, P., Kaufman, J., Brenol, J., Kochen, J., Lederman, R., Radominski, S., Szejnfeld, V., Zerbini, C., Adachi, J., Brown, J., Choquette, D., Hanley, D., Josse, R., Kendler, D., Kremer, R., Morin, F., Olszynski, W., Papaioannou, A., Kinyuen, C., Chen, B., Lin, S., Casas, N., Chalem, M., Jaller, J., Molina, J., Aro, H., Heikkinen, J., Kroger, H., Makinen, L., Saltevo, J., Salmi, J., Valimaki, M., Benhamou, C. l., Fardellone, P., Werhya, G., Allolio, B., Felsenberg, D., Happ, J., Hartard, M., Hensen, J., Kaps, P., Kekow, J., Moericke, R., Ortloff, B., Schneider, P., Wassenberg, S., Balogh, A., Gomor, B., Hidvegi, T., Koranyi, L., Poor, G., Tulassay, Z., Pollak, R. d., Eshed, V., Foldes, A. j., Ish Shalom, S., Vered, I., Weiss, M., Adami, S., Barone, A., Bianchi, G., Giannini, S., Isaia, G. c., Luisetto, G., Minisola, Salvatore, Molea, N., Nuti, R., Ortolani, S., Passeri, M., Rubinacci, A., Seriolo, B., Sinigaglia, L., Choi, W. h., Kang, M. i., Kim, G. s., Kim, H. s., Kim, Y. k., Lim, S. k., Son, H. y., Yoon, H. k., Abud, C., Garcia, P., Ochoa, L., Orozco, J., Santos, J., Reid, I., Elle, S., Halse, J., Høiseth, A., Olav, H., Røed, H. i., Skag, A., Stakkestad, J., Syversen, U., Badurski, J., Czerwinski, E., Lorenc, R., Marcinowska Suchowierska, E., Sawicki, A., Supronik, J., Ailamazyan, E., Benevolenskaya, L., Dreval, A., Dvoretsky, L., Dyomina, R., Mazurov, V., Melnichenko, G., Mkrtoumyan, A., Orlov Morozov, A., Ostroumova, O., Pikhlak, E., Shemerovskaya, T., Shostak, N., Skripnikova, I., Smetnik, V., Tsyrlina, E., Usova, G., Zalevskaya, A., Zazerskaya, I., Zotkin, E., Ljunggren, O., Lofgren, J., Palmer, M., Saaf, M., Stenstrom, M., Hasler, P., Lamy, O., Lippuner, K., Merlin, C., Rizzoli, R., Theiler, R., Tyndall, A., Uebelhart, D., Chen, J. f., Chen, P. q., Chin, L. s., Hwang, J. s., Yang, T. s., Jirapinyo, M., Sattaya, R., Sriussadaporn, S., Supasin, S., Taechakraichana, N., Wilawan, K., Donnachie, H., Fraser, W., Mclellan, A., Reid, D., Abruzzo, J., Ackerman, R., Adler, R., Aloia, J., Birbara, C., Bode, B., Bone, H., Brandon, D., Dionne, D., Jr Downs, R., Dreyfus, J., Elinoff, V., Emkey, R., Fanciullo, J., Fiske, D., Genaro, P., Gollapudi, M., Gordon, R., Hennessey, J., Howard, P., Johnson, K., Johnston, C., Kagan, R., Kafka, S., Kaine, J., Klein, T., Koltun, W., Leboff, M., Levine, B., Lewiecki, E. m., Lewis, C. e., Licata, A., Lillestol, M., Lubin, B., Malamet, R., Mangione, A., Matkovic, V., Mehta, D., Miller, P., Miller, S., Murphy, F. t., Nattrass, S., Podlecki, D., Recknor, C., Rosen, C., Rowe, D., Rude, R., Schnitzer, T., Sherrer, Y., Silverman, S., Stephenson, K., Troupin, B., Tucci, J., Villareal, R., Watts, N., Weinstein, R., Weitz, M., and White, R.

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Osteoporosis, Bed rest, Placebo, Drug Administration Schedule, Article, law.invention, postmenopausal osteoporosis, zoledronic acid, Randomized controlled trial, Risk Factors, law, Back pain, disability, fracture, Internal medicine, Prevalence, Humans, Medicine, Disabled Persons, Orthopedics and Sports Medicine, Probability, Bone Density Conservation Agents, Diphosphonates, business.industry, Imidazoles, medicine.disease, Back Pain, Female, Multivariate Analysis, Spinal Fractures, Bed Rest, Low back pain, Surgery, Zoledronic acid, Relative risk, medicine.symptom, business, medicine.drug
Abstract

The objective of this study was to determine the effect of once-yearly zoledronic acid on the number of days of back pain and the number of days of disability (ie, limited activity and bed rest) owing to back pain or fracture in postmenopausal women with osteoporosis. This was a multicenter, randomized, double-blind, placebo-controlled trial in 240 clinical centers in 27 countries. Participants included 7736 postmenopausal women with osteoporosis. Patients were randomized to receive either a single 15-minute intravenous infusion of zoledronic acid (5 mg) or placebo at baseline, 12 months, and 24 months. The main outcome measures were self-reported number of days with back pain and the number of days of limited activity and bed rest owing to back pain or a fracture, and this was assessed every 3 months over a 3-year period. Our results show that although the incidence of back pain was high in both randomized groups, women randomized to zoledronic acid experienced, on average, 18 fewer days of back pain compared with placebo over the course of the trial (p = .0092). The back pain among women randomized to zoledronic acid versus placebo resulted in 11 fewer days of limited activity (p = .0017). In Cox proportional-hazards models, women randomized to zoledronic acid were about 6% less likely to experience 7 or more days of back pain [relative risk (RR) = 0.94, 95% confidence interval (CI) 0.90–0.99] or limited activity owing to back pain (RR = 0.94, 95% CI 0.87–1.00). Women randomized to zoledronic acid were significantly less likely to experience 7 or more bed-rest days owing to a fracture (RR = 0.58, 95% CI 0.47–0.72) and 7 or more limited-activity days owing to a fracture (RR = 0.67, 95% CI 0.58–0.78). Reductions in back pain with zoledronic acid were independent of incident fracture. Our conclusion is that in women with postmenopausal osteoporosis, a once-yearly infusion with zoledronic acid over a 3-year period significantly reduced the number of days that patients reported back pain, limited activity owing to back pain, and limited activity and bed rest owing to a fracture.

Published
2011

13. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

Author

Martino, S. A, Cauley, J. A. B, Barrett Connor, E. C, Powles, T. J. D, Mershon, J. E, Disch, D. E, Secrest, R. J. E, Cummings, S. R. F, Mautalen, C. A. G, Zanchetta, J. R. H, Hooper, M. J. I, K. W. J, Ng, Prince, R. L. K, Nicholson, G. L, Roberts, A. P. M, Seeman, E. N, Williamson, M. O, Boschitsch, E. P, Leb, G. Q, Body, J. J. R, Devogelaer, J. P. S, Geusens, P. T, Kaufman, J. M. u, Peretz, A. V, Adachi, J. W, Bensen, W. X, Brown, J. P. Y, Cheung, A. Z, Chik, C. Aa, Gee, S. Ab, Hanley, D. Ac, Hawker, G. A. Ad, Hodsman, A. B. Ae, Joyce, C. Af, Monchesky, T. C. Ag, Olszynski, W. P. Ah, Roe, B. Ai, Senikas, V. Aj, Seminoski, K. Ak, Wall, J. Ab, Stepan, J. Al, Hyldstrup, L. Am, Langdahl, B. An, Sorensen, T. H. Ao, Alhava, E. Ap, Kormano, M. Aq, Salmela, P. Ar, Salmi, J. As, Valimaki, M. At, Audran, M. Au, Briancon, D. Av, Delmas, P. Aw, Fardellone, P. Ax, Ribot, C. Ay, De Vernejoul, M. C. Az, Balogh, A. Ba, Julesz, J. Bb, Szuecs, J. Bc, Karsik, A. Bd, Fiore, C. Be, Genazzani, A. R. Bf, Gennari, C. Bg, Isaia, Giovanni Carlo, Melis, G. B. Bi, Nuti, R. Bg, Oriente, P. Bj, Passeri, M. Bk, Sartori, L. Bl, Corea Rotter, R. Bm, Gonzalez, S. Bn, Murillo, A. Bo, Jonker, J. J. Bp, Lips, P. Bq, Mulder, H. Br, Pols, H. A. Bs, Halse, J. I. Bt, Hoiseth, A. Bu, Jorde, R. Bv, Olford, E. S. Bw, Skag, A. Bw, Stakkestad, J. A. Bx, Wist, E. By, Badurski, J. E. Bz, Hoszowski, K. Ca, Ogonowski, J. Cc, Bose, K. Cb, Lee, K. O. Cb, Dzurik, R. Cd, Kocijancic, A. Ce, Cannata Andia, J. B. Cf, Collado, R. C. Cg, Carranza, F. H. Ch, Diez Perez, A. Cf, Escobar Jimenez, F. Ci, Minguella, J. F. Cj, Solan, X. N. Cf, Torres, M. M. Cj, Larsson, K. Ck, and Malströem, D. Cl

Subjects
Selective Estrogen Receptor Modulators, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Breast Neoplasms, Placebo, Drug Administration Schedule, law.invention, Breast cancer, Randomized controlled trial, Double-Blind Method, Estrogen Receptor Modulators, law, Internal medicine, medicine, Humans, Raloxifene, Osteoporosis, Postmenopausal, Aged, Gynecology, business.industry, Raloxifene Hydrochloride, Incidence, Patient Selection, Lasofoxifene, Middle Aged, medicine.disease, United States, Treatment Outcome, Oncology, Selective estrogen receptor modulator, Female, business, Tamoxifen, medicine.drug
Abstract

Background: The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation (MORE) trial found that 4 years of raloxifene therapy decreased the incidence of invasive breast cancer among postmenopausal women with osteoporosis by 72% compared with placebo. We conducted the Continuing Outcomes Relevant to Evista (CORE) trial to examine the effect of 4 additional years of raloxifene therapy on the incidence of invasive breast cancer in women in MORE who agreed to continue in CORE. Methods: Women who had been randomly assigned to receive raloxifene (either 60 or 120 mg/day) in MORE were assigned to receive raloxifene (60 mg/day) in CORE (n = 3510), and women who had been assigned to receive placebo in MORE continued on placebo in CORE (n = 1703). Breast cancer incidence was analyzed by a log-rank test, and a Cox proportional hazards model was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results: During the CORE trial, the 4-year incidences of invasive breast cancer and estrogen receptor (ER)-positive invasive breast cancer were reduced by 59% (HR = 0.41; 95% CI = 0.24 to 0.71) and 66% (HR = 0.34; 95% CI = 0.18 to 0.66), respectively, in the raloxifene group compared with the placebo group. There was no difference between the two groups in incidence of ER-negative invasive breast cancer during CORE (P = .86). Over the 8 years of both trials, the incidences of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66% (HR = 0.34; 95 % CI = 0.22 to 0.50) and 76% (HR = 0.24; 95% CI = 0.15 to 0.40), respectively, in the raloxifene group compared with the placebo group. During the CORE trial, the relative risk of thromboembolism in the raloxifene group compared with that in the placebo group was 2.17 (95% CI = 0.83 to 5.70). This increased risk, also observed in the MORE trial, persisted over the 8 years of both trials. Conclusions: The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis. No new safety concerns related to raloxifene therapy were identified during CORE. © Oxford University Press 2004, all rights reserved.

Published
2004

14. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Reginster, J.-Y., Kaufman, J.-M., Goemaere, S., Devogelaer, Jean-Pierre, Benhamou, C. L., Felsenberg, D., Diaz-Curiel, M., Brandi, M.-L., Badurski, J., Wark, J., Balogh, A., Bruyère, O., Roux, C., UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Reginster, J.-Y., Kaufman, J.-M., Goemaere, S., Devogelaer, Jean-Pierre, Benhamou, C. L., Felsenberg, D., Diaz-Curiel, M., Brandi, M.-L., Badurski, J., Wark, J., Balogh, A., Bruyère, O., and Roux, C.

Abstract

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. INTRODUCTION: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. METHODS: Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX® scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX®-matched placebo group identified in the TROPOS placebo arm. RESULTS: The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 ± 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX®-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. CONCLUSIONS: Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety

Published
2012

15. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

Author

Reginster, J-Y, Kaufman, J-M, Goemaere, S, Devogelaer, JP, Benhamou, CL, Felsenberg, D, Diaz-Curiel, M, Brandi, M-L, Badurski, J, Wark, J, Balogh, A, Bruyere, O, Roux, C, Reginster, J-Y, Kaufman, J-M, Goemaere, S, Devogelaer, JP, Benhamou, CL, Felsenberg, D, Diaz-Curiel, M, Brandi, M-L, Badurski, J, Wark, J, Balogh, A, Bruyere, O, and Roux, C

Abstract

UNLABELLED: In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. INTRODUCTION: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. METHODS: Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX® scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX®-matched placebo group identified in the TROPOS placebo arm. RESULTS: The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 ± 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX®-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. CONCLUSIONS: Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a

Published
2012

16. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

Author

Meunier, PJ, Roux, C, Ortolani, S, Diaz-Curiel, M, Compston, J, Marquis, P, Cormier, C, Isaia, G, Badurski, J, Wark, JD, Collette, J, Reginster, JY, Meunier, PJ, Roux, C, Ortolani, S, Diaz-Curiel, M, Compston, J, Marquis, P, Cormier, C, Isaia, G, Badurski, J, Wark, JD, Collette, J, and Reginster, JY

Abstract

SUMMARY: Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. RESULTS: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups. CONCLUSION: In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women.

Published
2009

17. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial

Author

Reginster, Jean-Yves, primary, Badurski, J, additional, Bellamy, N, additional, Bensen, W, additional, Chapurlat, R, additional, Chevalier, X, additional, Christiansen, C, additional, Genant, H, additional, Navarro, F, additional, Nasonov, E, additional, Sambrook, P N, additional, Spector, T D, additional, and Cooper, C, additional

Published
2014
Full Text
View/download PDF

18. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate.

Author

Bruyère O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY, Bruyère, O, Roux, C, Badurski, J, Isaia, G, de Vernejoul, M C, Cannata, J, Ortolani, S, Slosman, D, Detilleux, J, and Reginster, J-Y

Abstract

Objective: Strontium ranelate (SR) increases bone mineral density (BMD) in postmenopausal osteoporotic women and reduces vertebral and non-vertebral fracture incidence. Hip fracture reduction has also been observed during 3-year treatment with SR in osteoporotic women at high risk of hip fracture. The objective of this study is to analyse the association between BMD changes and hip fracture incidence during treatment with SR. Material and Methods: In this post-hoc analysis, 465 women aged over 74 years with low BMD at the femoral neck (T-score < or = -2.4 according to NHANES normative values) were selected from the population of a recently published study (the Treatment of Peripheral Osteoporosis Study - TROPOS). BMD was assessed at the femoral neck at baseline and after a follow-up of 3 years. Hip fractures were reported by study investigators. Results: After adjusting for age, body mass index, femoral neck BMD at baseline and number of prevalent vertebral fractures, we found that for each 1% increase in femoral neck BMD observed after 3 years, the risk to experience a hip fracture after 3 years decreased by 7% (95% CI: 1-14%) (p = 0.04). In patients experiencing a hip fracture over 3 years of treatment with SR, femoral neck BMD increased by (mean [SE]) 3.41 (1.02)% compared to 7.23 (0.81)% in patients without hip fracture (p = 0.02). Conclusion: In this post-hoc analysis of women undergoing 3 years of SR treatment, an increase in femoral neck BMD is associated with a decrease in hip fracture incidence. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

19. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial

Author

Cooper, Cyrus, primary, Reginster, J-Y, additional, Chapurlat, R, additional, Christiansen, C, additional, Genant, H, additional, Bellamy, N, additional, Bensen, W, additional, Navarro, F, additional, Badurski, J, additional, Nasonov, E, additional, Chevalier, X, additional, and Sambrook, P N, additional

Published
2013
Full Text
View/download PDF

20. AB0962 Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled international trial

Author

Cooper, C., primary, Chapurlat, R., additional, Christiansen, C., additional, Genant, H., additional, Bellamy, N., additional, Bensen, W., additional, Navarro, F., additional, Badurski, J., additional, Nasonov, E., additional, Chevalier, X., additional, Sambrook, P., additional, Spector, T., additional, and Reginster, J.-Y., additional

Published
2013
Full Text
View/download PDF

21. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

Author

Reginster, J-Y., primary, Kaufman, J-M., additional, Goemaere, S., additional, Devogelaer, J. P., additional, Benhamou, C. L., additional, Felsenberg, D., additional, Diaz-Curiel, M., additional, Brandi, M-L., additional, Badurski, J., additional, Wark, J., additional, Balogh, A., additional, Bruyère, O., additional, and Roux, C., additional

Published
2011
Full Text
View/download PDF

29. Aminosugars in Cases of Gastric Ulcers. I. The Amount of Glucosamine and Galactosamine in the Human Gastric Mucosa

Author

K. Zwierz, A. Gindzieński, Badurski J, and M. Kaczmarski

Subjects
Adult, Male, medicine.medical_specialty, Chromatography, Paper, Ultraviolet Rays, medicine.medical_treatment, Gastroenterology, chemistry.chemical_compound, Gastrectomy, Glucosamine, Internal medicine, medicine, Gastric mucosa, Humans, Stomach Ulcer, chemistry.chemical_classification, Staining and Labeling, Histocytochemistry, Hexosamines, Middle Aged, Paper chromatography, medicine.anatomical_structure, chemistry, Gastric Mucosa, Galactosamine, Female
Published
1967
Full Text
View/download PDF

32. Book Reviews – Buchbesprechungen – Livres Nouveaux

Author

A. Nowak, A.V. Chitre, K. Zwierz, M. Kecklík, Z. Sivanová, M. Kaczmarski, R. Lambert, K. Herfort, D. Kochańska, V. Hoenig, Badurski J, A. Gindzieński, Berard A, K.N. Jeejeebhoy, J. Hoenigová, H.G. Desai, K. Kowalewski, K. Gibiński, Martin F, and R. Seyss

Subjects
Gastroenterology
Published
1967
Full Text
View/download PDF

33. Strontium Ranelate Prevents Quality of Life Impairment.

Author

Marquis, P., Roux, C., De la Loge, C., Diaz-Curiel, M., Cormier, C., Isaia, G., Badurski, J., Wark, J., and Meunier, P. J.

Subjects
STRONTIUM ranelate
Abstract

An abstract of the article "Strontium Ranelate Prevents Quality of Life Impairment," by P. Marquis, C. Roux, C. de la Loge, M. Diaz-Curiel, C. Cormier, G. Isaia, J. Badurski, J. Wark and P.J. Meunier is presented.

Published
2008

34. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.

Author

Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X, Christiansen C, Genant H, Navarro F, Nasonov E, Sambrook PN, Spector TD, and Cooper C

Subjects
Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Osteoarthritis, Knee diagnostic imaging, Radiography, Treatment Outcome, Antirheumatic Agents therapeutic use, Organometallic Compounds therapeutic use, Osteoarthritis, Knee drug therapy, Thiophenes therapeutic use
Abstract

Background: Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis., Methods: Patients with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) 2.5-5 mm) were randomly allocated to strontium ranelate 1 g/day (n=558), 2 g/day (n=566) or placebo (n=559). The primary endpoint was radiographical change in JSW (medial tibiofemoral compartment) over 3 years versus placebo. Secondary endpoints included radiological progression, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and knee pain. The trial is registered (ISRCTN41323372)., Results: The intention-to-treat population included 1371 patients. Treatment with strontium ranelate was associated with smaller degradations in JSW than placebo (1 g/day: -0.23 (SD 0.56) mm; 2 g/day: -0.27 (SD 0.63) mm; placebo: -0.37 (SD 0.59) mm); treatment-placebo differences were 0.14 (SE 0.04), 95% CI 0.05 to 0.23, p<0.001 for 1 g/day and 0.10 (SE 0.04), 95% CI 0.02 to 0.19, p=0.018 for 2 g/day. Fewer radiological progressors were observed with strontium ranelate (p<0.001 and p=0.012 for 1 and 2 g/day). There were greater reductions in total WOMAC score (p=0.045), pain subscore (p=0.028), physical function subscore (p=0.099) and knee pain (p=0.065) with strontium ranelate 2 g/day. Strontium ranelate was well tolerated., Conclusions: Treatment with strontium ranelate 1 and 2 g/day is associated with a significant effect on structure in patients with knee osteoarthritis, and a beneficial effect on symptoms for strontium ranelate 2 g/day.

Published
2013
Full Text
View/download PDF

35. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.

Author

Cooper C, Reginster JY, Chapurlat R, Christiansen C, Genant H, Bellamy N, Bensen W, Navarro F, Badurski J, Nasonov E, Chevalier X, and Sambrook PN

Subjects
Adult, Aged, Aged, 80 and over, Bone Density Conservation Agents administration & dosage, Bone Remodeling drug effects, Disease Progression, Double-Blind Method, Female, Humans, Knee Joint, Male, Middle Aged, Organometallic Compounds administration & dosage, Research Design, Thiophenes administration & dosage, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents therapeutic use, Organometallic Compounds adverse effects, Organometallic Compounds therapeutic use, Osteoarthritis, Knee drug therapy, Thiophenes adverse effects, Thiophenes therapeutic use
Abstract

Objective: The osteoporosis drug strontium ranelate dissociates bone remodelling processes. It also inhibits subchondral bone resorption and stimulates cartilage matrix formation in vitro. Exploratory studies in the osteoporosis trials report that strontium ranelate reduces biomarkers of cartilage degradation, and attenuates the progression and clinical symptoms of spinal osteoarthritis, suggesting symptom- and structure-modifying activity in osteoarthritis. We describe the rationale and design of a randomised trial evaluating the efficacy and safety of strontium ranelate in knee osteoarthritis., Research Design, Methods, and Results: This double-blind, placebo-controlled trial (98 centres, 18 countries) includes ambulatory Caucasian men and women aged ≥50 years with primary knee osteoarthritis of the medial tibiofemoral compartment (Kellgren and Lawrence grade 2 or 3), joint space width (JSW) 2.5 to 5 mm, and knee pain on most days in the previous month (intensity ≥40 mm on a visual analogue scale). Patients are randomly allocated to three groups (strontium ranelate 1 or 2 g/day, or placebo). Follow-up is expected to last 3 years. The primary endpoint is radiographic change in JSW from baseline in each group versus placebo. The main clinical secondary endpoint is WOMAC score at the knee. Safety is assessed at every visit. It is estimated that 1600 patients are required to establish statistical significance with power >90% (0.2 mm ± 10% between-group difference in change in JSW over 3 years). Recruitment started in April 2006. The results are expected in spring 2012., Clinical Trial Registration: The trial is registered on www.controlled-trials.com (number ISRCTN41323372)., Conclusions: This randomised, double blind, placebo-controlled study will establish the potential of strontium ranelate in improving structure and symptoms in patients with knee osteoarthritis.

Published
2012
Full Text
View/download PDF

36. The characteristics of osteoporotic fractures in the region of Bialystok (BOS-2). The application of the WHO algorithm, FRAX®BMI and FRAX®BMD assessment tools to determine patients for intervention.

Author

Badurski J, Jeziernicka E, Dobreńko A, Nowak N, Daniluk S, Rybaczuk M, and Wiśniowiecka M

Subjects
Adult, Aged, Aged, 80 and over, Algorithms, Bone Density, Cohort Studies, Female, Humans, Middle Aged, Poland epidemiology, Predictive Value of Tests, Risk Assessment, Risk Factors, Surveys and Questionnaires, World Health Organization, Hip Fractures epidemiology, Mass Screening methods, Osteoporotic Fractures epidemiology
Abstract

Background: The 2007 WHO guidelines for the treatment of osteoporosis require that we know the population risk of an osteoporotic fracture for each country to classify patients requiring treatment., Material and Methods: Studies have been carried out among a random cohort of 1,608 women over the age of 40 to assess a ten-year absolute risk of main osteoporotic fractures (AR-10 m.o.fx.) and hip fractures (AR-10 h.fx.) by using FRAX®BMI and FRAX®BMD based on the epidemiology of fractures in England., Results: Both methods gave similar results in assessing the probability of fracture, showing the increase of AR-10 m.o.fx. in subsequent life decades to rise from 5% in the fifth decade to 25% in the ninth, mean result 11%, and AR-10 h.fx. to rise over the same period from 0.5% to 13%, mean result 3%. The number of fractures increases up to the seventh and eighth decades, and decreases according to the number of patients in the age group. The commonest fracture risks reported, other than old age and low BMI, were a prior fracture, a family history of hip fracture and smoking., Conclusions: Comparative analysis of examined parameters of FRAX between people with and without fractures showed considerable differences only in age and AR-10 m.o.fx. This doubled in people with previous fractures (ca. 18% vs. 9%) and AR-10 h.fx. (ca. 5% vs. 2.5%). The "middle" area between the average population risks (AR-10 m.o.fx. 11% and AR-10 h.fx. 3%) and the risks in patients with fractures (AR-10 m.o.fx. 18% and AR-10 h.fx. 9%) could work as an indicator: below those values the risk is low and no treatment is required; above those values, the risk is high, and intervention is necessary; the middle area implies a BMD examination and reassessment of the fracture risk.

Published
2011

37. Guidelines on the Diagnosis of Osteoporosis and Assessment of Fracture Risk in Poland of III Central European Congress on Osteoporosis and Osteoarthritis, XV Congress of the Polish Osteoarthrology Society and Polish Foundation of Osteoporosis.

Author

Czerwiński E, Badurski J, Lorenc R, and Osieleniec J

Subjects
Europe, Humans, Inservice Training standards, International Cooperation, Poland, Practice Patterns, Physicians', Societies, Medical standards, Fractures, Bone prevention & control, Osteoarthritis diagnosis, Osteoarthritis therapy, Osteoporosis diagnosis, Osteoporosis therapy, Practice Guidelines as Topic
Published
2010

38. [Treatment of patients with osteoporosis].

Author

Horst-Sikorska W and Badurski J

Subjects
Absorptiometry, Photon, Calcium therapeutic use, Cholecalciferol therapeutic use, Fractures, Bone etiology, Fractures, Bone prevention & control, Humans, Osteoporosis complications, Osteoporosis diagnosis, Risk Factors, Osteoporosis therapy
Published
2001

39. [Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analogue scale (VAS)].

Author

Badurski J, Jeziernicka E, Naruszewicz K, and Racewicz A

Subjects
Catechin, Cells, Cultured drug effects, Drug Therapy, Combination, Female, Humans, Knee Joint, Male, Pain Measurement, Calcitonin administration & dosage, Flavonoids administration & dosage, Naproxen administration & dosage, Osteoarthritis drug therapy
Abstract

Unlabelled: The newest laboratory and clinical elaborations have described a stimulatory effect of salmon calcitonin (sCT) on cultivated chondrocytes and cartilage explants in regard to their secretory function of glycosaminoglycans, collagen t. II and hyaluonic acid as well as have shown anticatabolic effect of sCT on numerous animal models of osteoarthropathy. Moreover, very few clinical indicated profitable effect of CT on degenerative joint diseases and on rheumatoid arthritis. The aim of the present study is to compare the curative effect of sCT (Miacalcic, Sandoz, nasal spray, 2 x 100 IU/day ) vs flavonoides (VR, Venoruton, Zyma, 2 x 0.6 + Vit. C. 0.2/day) with or without naproxen sodium (AP, Apranax, 2 x 0.550/day) in 30 patients suffering from gonarthritis, treated in 10 months in one of the three regimes: I--(n = 10, BMI-33.3, aged 59.5 y., Larsen gr. -2.5): 1st month-VR, 2 and 3-sCT, 4 and 5-VR, 6 and 7-AP, 8.9 and 10-VR; II--(n = 10, BMI-28.8, aged 56 y., Larsen gr. 2.95): 1st m.-VR, 2 and 3-Ap, 4 and 5-VR, 6 and 7-sCT, 9.9 and 10-VR; III--(n = 10, BMI-31.4, aged 58 y., Larsen gr.-2.8): 1st m.-VR, 2 and 3-sCT, 4 and 5-VR, 6 and 7-sCT, 8.9 and 10-VR. Clinical effects of treatment were evaluated by EULAR criteria, VAS, and the paracetamol consumption., Results: The best results according to all three criteria of improvement have been observed in group III treated only with sCT and VR followed by group I in which sCT was given as the first active drug. This effect lasted until three months after the withdrawal of sCT and/or naproxen. This results supported our opinion on antiosteoarthritic ability of salmon calcitonin and marked curative effect of flavonoides in the treatment of osteoarthritis.

Published
1995

41. [Calcitonin in treating bone and joint lesions--clinical and experimental findings and personal experience].

Author

Badurski J

Subjects
Animals, Bone Diseases physiopathology, Humans, Joint Diseases physiopathology, Bone Diseases drug therapy, Calcitonin therapeutic use, Joint Diseases drug therapy
Abstract

Several experimental studies in the animal models and the use of calcitonin in patients with osteoarthritis, rheumatoid arthritis, and osteoporosis have shown multiple actions of this hormone, justifying its use in the wide range of osteoarthritic pathologies. We used well known animal models of tests to study chondro-tropic drugs such as: post-corticoid arthropathy, partial meniscectomy, immobilization of the lower extremity of rabbits, follow-up of the natural knee degeneration in the black mouse C57, and radiolabelled sulphates uptake by the cartilage, and have shown: (a) anticatabolic effect of salmon calcitonin as measured as GAG levels, width of articular space, and histochemical and morphologic examination of the cartilage in some model arthropathies, (b) anti-osteoporotic properties counteracting an effect of corticosteroids, (c) increased uptake of sulphates by the articular cartilage of the rat following calcitonin administration in vivo. The studies explaining mechanisms of calcitonin actions included IGF-1 assays and beta-endorphins. The former increased transiently after calcitonin administration whereas the latter increased after non-steroid anti-inflammatory agents use. Calcitonin decreased gastrin secretion with negligible effect on calcium ions and prostaglandin E2 levels in blood plasma while it potently acid secretion and increasing gastric mucus content in the stomach. The use of calcitonin in patients with arthrosis, rheumatoid arthritis, and osteoporosis with accompanying peptic and/or duodenal ulcers produced healing of peptic and/or duodenal ulcers in 75% of patients within 4 weeks with simultaneous shortening of the morning stiffness, increase in hand grip strength (in rheumatoid arthritis), and significant decrease in pain as well as an improvement in the quality of life in the majority of the treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1993

42. [Bone density in axial and peripheral skeleton and mineral density of the entire body as an age dependent factor in a population sample of healthy women].

Author

Hoszowski K, Gawron J, Tałajko A, Boczoń S, Badurski J, Bieńkowska R, and Lorenc RS

Subjects
Absorptiometry, Photon, Adult, Aged, Aged, 80 and over, Aging physiology, Female, Femur physiology, Humans, Lumbar Vertebrae physiology, Middle Aged, Reference Values, Bone Density
Abstract

Bone mineral density has been measured with dual energy X-ray absorptiometry (DEXA) in both axial and peripheral skeleton of 208 randomly selected healthy women aged between 20 and 80 years. Examined women have been stratified into the age groups of every 10 years. Bone mineral density has been measured in lumbar spine L2-L4 (AP), L2-L3 (Lat.) and proximal femur together with total body mineral density in every examined woman. The obtained results are considered reference values for the Polish population.

Published
1993

43. The origin of alpha-1-acid glycoprotein (AGP) in human gastric juice.

Author

Badurski J

Subjects
Animals, Fluorescent Antibody Technique, Gastric Mucosa cytology, Humans, Orosomucoid analysis, Rabbits, Gastric Juice analysis, Gastric Mucosa metabolism, Orosomucoid metabolism
Abstract

In order to answer the question whether acid alpha 1-glycoprotein (AGP) is produced by the healthy human gastric mucosa, column chromatography of neutralized, pooled, and papain digested normal human gastric juice was performed on DEAE-cellulose using Varigrad NaCl elution gradients. Four glycoprotein fractions were obtained, one of which (fraction III) contained AGP. Its antibody raised in rabbits did not give immunofluorescence with any of the cells of the human gastric mucosa, only a reaction with AGP located in the intercellular spaces of gastric glands. These results indicate the extragastric origin of AGP, probably from serum.

Published
1978

44. [Secretion of gastric mucus following maximal pentagastrin stimulation].

Author

Zarzycki W, Badurski J, Jaworowska E, and Sarosiek J

Subjects
Fucose metabolism, Gastric Acid metabolism, Gastric Juice metabolism, Gastric Mucosa drug effects, Hexosamines metabolism, Hexoses metabolism, Humans, Pepsin A metabolism, Sialic Acids metabolism, Stimulation, Chemical, Gastric Mucins metabolism, Gastric Mucosa metabolism, Pentagastrin pharmacology
Abstract

The aim of the thesis was the observation of the gastric mucus secretion on the basis of carbohydrate components and protein secretion into the gastric lumen. 15 healthy volunteers were investigated: 7 males and 8 females aged 20-37 (average rate 27). In this group gastric juice was aspirated after administration of single 6 micrograms/kg BW stimulus of pentagastrin. Concentration and output of hydrochloric acid, pepsin, protein and carbohydrate components of gastric juice fucose, sialic acid, hexosamines and hexoses were measured. Carbohydrate components and proteins included informations concerning gastric mucus secretion into gastric lumen. It was shown that the highest gastric mucus secretion occurred before maximal gastric acid secretion. This is of importance for keeping balance between so called aggressive and protective mechanisms. It is of great importance in pathophysiology of stomach.

Published
1986

45. [Sulfate glycoproteins of the human alimentary tract].

Author

Badurski J, Slomiany B, and Slomiany A

Subjects
Blood Group Antigens, Gastric Juice analysis, Glycoproteins immunology, Glycoproteins isolation & purification, Humans, Stomach Neoplasms metabolism, Sulfates metabolism, Digestive System metabolism, Glycoproteins metabolism
Published
1978

46. [Gastric juice secretion in chronic duodenal ulcer].

Author

Sarosiek J, Badurski J, Zwierz K, Kilczewska D, Zarzycki W, Jelski E, and Gindzieński A

Subjects
Adult, Chronic Disease, Female, Gastric Juice analysis, Humans, Male, Middle Aged, Duodenal Ulcer physiopathology, Gastric Juice metabolism
Published
1974

49. Calcitonin versus cimetidine or De-Nol in gastric ulcer treatment. An endoscopically controlled trial.

Author

Janke A, Badurski J, Stasiewicz J, Sajewicz I, and Namiot Z

Subjects
Administration, Oral, Adult, Aged, Aged, 80 and over, Arthritis, Rheumatoid drug therapy, Clinical Trials as Topic, Female, Gastroscopy, Humans, Injections, Intramuscular, Male, Middle Aged, Osteoporosis drug therapy, Random Allocation, Wound Healing drug effects, Anti-Ulcer Agents administration & dosage, Calcitonin administration & dosage, Cimetidine administration & dosage, Organometallic Compounds administration & dosage, Stomach Ulcer drug therapy
Abstract

110 patients with benign gastric ulcer and concomitant joint diseases (rheumatoid arthritis, osteoarthrosis) were treated in a comparative short-term clinical trial to assess the relative efficacy of calcitonin (daily 100 MRC of salmon calcitonin intramuscularly), cimetidine (daily 1000 mg orally) and colloidal bismuth subcitrate (De-Nol-four times a day in doses of 5 ml diluted with 15 ml of water). Groups of patients were comparable according to age, sex, duration of ulcer disease, smoking habits, gastric acid secretion and mean ulcer size. The ulcer healing was controlled endoscopically after 2 and 4 weeks of the treatment. There was no significant difference in the ulcer healing rate between three groups neither after 2 weeks (calcitonin-36.7% of healed ulcers, cimetidine-37.5% and De-Nol-35.0% nor after 4 weeks respectively (76.7%, 72.5% and 77.5%). In the calcitonin group a gradual joint pain relief was observed in 84% of patients who complained arthralgia. The moderate side effects (headache, nausea, flush) were observed only in the patients treated with calcitonin (8 subjects). We suggest that calcitonin may be considered as a valid anti-ulcer drug in the peptic ulcer patients with concomitant rheumatological diseases especially with osteoporosis.

Published
1988

Catalog

Books, media, physical & digital resources
See catalog results